Differential effects of extended-release carvedilol and extended-release metoprolol on lipid profiles in patients with hypertension: results of the Extended-Release Carvedilol Lipid Trial

Journal of the American Society of Hypertension

Volumn 3, Issue 3, 2009, Pages 210-220

  Fonarow, Gregg C ^a   Deedwania, Prakash ^b   Fonseca, Vivian ^c   Nesto, Richard W ^d   Watson, Karol ^a   Tarka, Elizabeth ^e   Lukas, Mary Ann ^e   Madan, Anuradha ^e   Shabbout, Mayadah ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Beta blockers; blood pressure; cardiovascular disease; dyslipidemia

Indexed keywords

AMLODIPINE; C PEPTIDE; CARVEDILOL; HIGH DENSITY LIPOPROTEIN; HYDROCHLOROTHIAZIDE; INSULIN; METOPROLOL SUCCINATE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 67349111413     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2009.01.004     Document Type: Article

References (23)

1. Castelli W.P., and Anderson K. A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med 80 (1986) 23-32
2. Hajjar I., and Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290 (2003) 199-206
3. Stamler J., Wentworth D., and Neaton J.D. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension: prospective data on the primary screenees of the Multiple Risk Factor Intervention Trial. Am J Med 80 (1986) 33-39
4. Tse W.Y., and Kendall M. Is there a role for beta-blockers in hypertensive diabetic patients?. Diabetes Med 11 (1994) 137-144
5. Fonarow G.C. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 116 (2004) 76S-788
6. Bell D.S. Use of beta-blockers in the patient with diabetes. Endocrinologist 13 (2003) 116-123
7. Jacob S., Balletshofer B., Henriksen E.J., Volk A., Mehnert B., and Loblein K. Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers. Blood Press 8 (1999) 261-268
8. Ruffolo R.R., Gellai M., Hieble J.P., Willette R.N., and Nichols A.J. The pharmacology of carvedilol. Eur J Clin Pharmacol 38 (1990) S82-S88
9. Jacob S., Rett K., Wicklmayr M., Agrawal B., Augustin H.J., and Dietze G.J. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the Carvedilol-Metoprolol Study. J Hypertens 14 (1996) 489-494
10. Giugliano D., Acampora R., Marfella R., de Rose N., Ziccardi P., and Ragone R. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension: a randomized, controlled trial. Ann Intern Med 126 (1997) 955-959
11. Bakris G.L., Fonseca V., Katholi R.E., McGill J.B., Messerli F.H., Phillips R.A., et al. Metabolic effects of carvedilol in patients with type 2 diabetes mellitus and hypertension. JAMA 292 (2004) 2227-2236
12. Bakris G.L., Tarka E.A., Waterhouse B., Goulding M.R., Madan A., Anderson K.M., et al. Cardiovascular risk factors in hypertension: rationale and design of studies to investigate the effects of controlled-release carvedilol on regression of left ventricular hypertrophy and lipid profile. Am J Cardiol 98 (2006) 46L-52
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
14. Frikke-Schmidt R., Nordestgaard B.G., Agerholm-Larsen B., Schnohr P., and Tybjaerg-Hansen A. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. J Lipid Res 41 (2000) 1812-1822
15. Quade D. Rank analysis of covariance. J Am Stat Assoc 62 (1967) 1187-1200
16. Skulas-Ray A.C., West S.G., Davidson M.H., and Kris-Etherton P.M. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia. Exp Opin Pharmacother 9 (2008) 1237-1248
17. Sarwar N., Danesh J., Eiriksdottir G., Sigurdsson G., Wareham N., Bingham S., et al. Triglycerides and the risk of coronary heart disease-10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 115 (2007) 450-458
18. Jeppesen J., Hein H., Suadicani P., and Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97 (1998) 1026-1036
19. Durrington P.N. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis 141 (1998) S57-S62
20. Despres J.-P., Lamarche B., Mauriege P., Cantin B., Dagenais G., Moorjani S., et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334 (1996) 952-957
21. Hu G. The DECODE Insulin Study Group. Plasma insulin and cardiovascular mortality in non-diabetic European Men and Women: a meta-analysis of data from eleven prospective studies. Diabetologia 47 (2004) 1245-1256
22. Sharp R.P., Sirajuddin R., and Sharief I.M. Impact of carvedilol on the serum lipid profile. Ann Pharmacother 42 (2008) 564-571
23. Dell'Omo G., Penno G., Del Prato S., and Pedrinelli R. Doxazosin in metabolically complicated hypertension. Exp Rev Cardiovasc Ther 5 (2007) 1027-1035